The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

corridorpharma.com

Stage

Debt | Dead

Total Raised

$20.71M

Last Raised

$1.55M

About Corridor Pharmaceuticals

Corridor Pharmaceuticals, formerly Arginetix, is a platform-based pulmonary and critical care company focused on developing therapeutics to treat inflammation, fibrosis and endothelial dysfunction. Utilizing their platform technology, the Company has discovered a highly potent, small molecule approach to inhibiting arginase. Corridor is targeting diseases where elevated arginase levels have been shown to be involved in disease progression such a pulmonary fibrosis, COPD and ischemia reperfusion injury (IRI).

Corridor Pharmaceuticals Headquarter Location

1122 Kenilworth Drive Suite 401

Towson, Maryland, 21204,

United States

410-616-0916

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Corridor Pharmaceuticals Patents

Corridor Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/26/2011

11/25/2014

Autosomal recessive disorders, Amino acids, Rare diseases, EC 1.14.13

Grant

Application Date

7/26/2011

Grant Date

11/25/2014

Title

Related Topics

Autosomal recessive disorders, Amino acids, Rare diseases, EC 1.14.13

Status

Grant

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.